Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

Lung-function testing will be paired with imaging-based fibrosis measurements to investigate PIPE-791’s treatment effects.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Qureight’s Fibr8 model to provide structural assessment as secondary endpoint in Contineum’s Phase 2 PROPEL-IPF clinical trial examining the safety and efficacy of PIPE-791 in idiopathic pulmonary fibrosis (IPF) patients
• Announcement comes after a recent European Respiratory Journal viewpoint by Qureight CSO identifying fibrosis quantification as the key structural imaging biomarker needed for antifibrotic trials
• PIPE-791 targets lysophosphatidic acid receptor 1 (LPAR1), a clinically validated target for IPF

CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)-- Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum) (NASDAQ:CTNM), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum’s lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.

Forced Vital Capacity (FVC), the primary endpoint in PROPEL-IPF, provides an established measure of lung function in IPF patients. Qureight’s AI-powered Fibr8™ imaging biomarker complements FVC by measuring the extent of fibrosis visible on High-Resolution Computed Tomography (HRCT), providing an assessment of structural disease burden. By examining both physiological and quantitative imaging measurements, PROPEL-IPF will investigate treatment effects on both lung function and imaging-defined measures of fibrosis progression, potentially generating valuable evidence to support the development of imaging endpoints for future clinical trials.

PROPEL-IPF (NCT07284459) is a global, randomised, double-blind, placebo-controlled Phase 2 clinical trial evaluating the efficacy, safety, and tolerability of once-daily oral PIPE-791 with 26 weeks of treatment in approximately 324 people with IPF. PIPE-791 targets the lysophosphatidic acid receptor 1 (LPAR1), a clinically validated target for IPF.

Qureight recently published a Viewpoint in the European Respiratory Journal advocating for the integration of quantitative fibrosis measurements alongside established physiological endpoints in antifibrotic clinical trials¹. PROPEL-IPF represents an important opportunity to try to advance this approach by potentially generating prospective evidence on the relationship between treatment-related changes in lung fibrosis and pulmonary function. This would strengthen the evidence base for quantitative CT as a sensitive measure of therapeutic response and support Qureight’s longer-term ambition to pursue formal regulatory qualification of imaging biomarkers as endpoints in antifibrotic drug development.

Simon Walsh, MD, PhD, Chief Scientific Officer, Qureight, commented: “PROPEL-IPF is a strong example of the endpoint model we believe the field needs: preserve FVC as the functional anchor, while measuring fibrosis directly on HRCT. The combination has the potential to help reveal whether a therapy is slowing the structural disease process as well as its downstream functional consequences.”

Timothy Watkins, MD, MSc, Chief Medical Officer, Contineum Therapeutics, added: “Qureight’s approach to quantitatively measure fibrosis could provide important insights in PROPEL-IPF. We are excited for our team to partner with the clinical scientists at Qureight, leveraging this imaging technology platform to enable lung-specific mechanistic insight into the effects of PIPE-791. Ultimately, this measure has the potential to serve as an additional means by which we can assess the impact of PIPE-791 treatment on underlying fibrosis pathology in IPF.”

1. Press release (2 November 2026) Qureight publishes in the European Respiratory Journal calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trials

Forward-Looking Statements

Certain statements contained in this press release, other than historical information, constitute forward-looking statements of Contineum Therapeutics, Inc. (“Contineum”, the “Company”, “we”, “our”, or “us”) within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, implied or express statements regarding the Company’s PROPEL-IPF clinical trial; the Company’s use of Qureight’s Fibr8 model in its PROPEL-IPF clinical trial and its ability to provide a complementary structural assessment of disease burden or to generate or provide valuable evidence or important insights; the future expectations, plans and prospects for the Company; the indications, anticipated benefits of, and market opportunities for the Company’s drug candidates; the Company’s business strategies and plans; and the quotations of the Company’s management. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company’s control and may cause its actual results, events, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties, include, but are not limited to, the following: the Company is heavily dependent on the success of PIPE-791 which is in the early stages of clinical development, and PIPE-791, and the Company’s other drug candidates, may not progress through clinical development or receive regulatory approval; the results of preclinical studies and clinical trials, including those conducted by third parties, may not be predictive of future results and unexpected adverse side effects or inadequate efficacy of the Company’s drug candidates may limit their development, regulatory approval and/or commercialization; the timing and outcome of research, development and regulatory review is uncertain; the FDA or comparable foreign regulatory authorities may disagree as to the design or implementation of our proposed clinical trials and/or require us to conduct additional studies or clinical trials or provide additional patient data, which could be costly, time-consuming and difficult to complete; clinical trials and preclinical studies may not proceed at the time or in the manner expected, or at all; the Company may use its capital resources sooner than expected and they may be insufficient to allow the Company to achieve its anticipated milestones; the potential for the Company’s programs and prospects to be negatively impacted by developments relating to the Company’s competitors, including the results of studies or regulatory determinations relating to the Company’s competitors; risks associated with reliance on third parties to successfully conduct clinical trials; the Company has incurred significant operating expenses since inception and it expects that its operating expenses will continue to significantly increase for the foreseeable future; the Company’s ability to operate in a competitive industry and compete successfully against competitors that have greater resources than the Company does; the Company may be unable to obtain, maintain and enforce intellectual property protection for its technology and drug candidates; and unstable market and economic conditions and military conflicts may adversely affect the Company’s business and financial condition and the broader economy and biotechnology industry. Additional risks and uncertainties that could affect the Company’s business, operations and results are included under the captions, “Risk Factors” and "Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company's periodic filings and in other filings that the Company makes with the Securities and Exchange Commission (SEC) from time to time, which are available on the Company’s website at www.contineum-tx.com under the Investor section and on the SEC’s website at www.sec.gov. Accordingly, readers should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261106223002/en/

For further information, please contact:

Zyme Communications
Katie Odgaard
Email: katie.odgaard@zymecommunications.com
Tel: +44 (0)7787 502 947

Qureight
Rebecca Simmons, COO
Email: r.simmons@qureight.com

Contineum
Steve E. Kunszabo, Senior Director, Investor Relations & Corporate Communications
Email: skunszabo@contineum-tx.com
Tel: +1 858 649 1158

Source: Qureight

Key Terms

forced vital capacity medical

The amount of air a person can forcefully breathe out after taking the deepest breath possible; think of it as how much air you can squeeze out of a balloon in one hard blow. It matters to investors because it’s a common, objective measure used in clinical trials and patient monitoring for respiratory drugs, devices and treatments—changes in this number can signal whether a therapy works, affecting regulatory approval, sales and company value.

high-resolution computed tomography medical

High-resolution computed tomography (HRCT) is a CT imaging technique that uses thin-slice scans and specialized scanner settings to produce very detailed images of small structures in the body, most commonly the lungs. It achieves higher spatial resolution than standard CT by acquiring thin contiguous or closely spaced slices, using high-frequency image reconstruction kernels and sometimes expiratory or prone positioning, which makes it useful for detecting and characterizing fine structural abnormalities such as interstitial lung disease, small airways disease, and early fibrosis; it is a diagnostic imaging protocol rather than a different machine. HRCT typically involves trade-offs such as increased image noise and, depending on the protocol, potentially higher radiation exposure than low-resolution CT, and its interpretation relies on pattern recognition by radiologists using standardized reporting approaches.

lysophosphatidic acid receptor 1 medical

A protein on the surface of cells that acts like a receptor for a signalling molecule called lysophosphatidic acid, triggering changes in cell growth, movement and inflammation. It matters to investors because blocking or activating this receptor is a potential way to treat diseases—so companies developing drugs or diagnostics aimed at it face clinical, regulatory and commercial risks and rewards; think of the receptor as a light switch that drugmakers try to turn on or off to change a disease’s course.

double-blind medical

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

randomised medical

Randomised means participants or items are assigned to different groups by chance rather than choice, like flipping a coin to decide who gets which treatment or process. This matters to investors because it reduces bias and makes outcomes more reliable, helping separate real effects from luck so that claims about a product, treatment, or business change are more trustworthy when assessing risk and value.